BRCA1 and neoplasm: Beyond predicting PARP inhibitor sensitivity, BRCA1/2 alterations affect the tumor microenvironment, resulting in increased tumor-infiltrating lymphocyte density and altered T-cell function [[57], [58], [59], [60]].